Legislation changes for medical practitioners

​​​From 5 November 2026, the Poisons and Therapeutic Goods Act and Regulation will be replaced by the: ​

The new Act and Regulation support safe, modern healthcare practices and business operations. These laws set clear rules to control the supply of scheduled substances and therapeutic goods in NSW, with the primary goal of protecting public health and safety.

This fact sheet outlines key legislative changes relevant to medical practitioners.​​

Last updated: 06 July 2026
Download

On this page

Key changes

Requirements no longer needed

  • You will no longer need to apply for approval to prescribe or supply Schedule 8 compounded medicines unless the medicine or circumstance requires approval as listed under Changes to medicines requiring approval below.
  • You will no longer need to include the NSW Health approval number on prescriptions for:
    • Schedule 8 psychostimulant medicines (dexamfetamine, methylphenidate, lisdexamfetamine)
    • Schedule 8 pharmacy compounded medicines (approval for these medicines is generally no longer required)
    • psilocybine and MDMA (N,α-dimethyl-3,4-(methylenedioxy)phenylethylamine)
    • nominated Schedule 4 medicines (e.g., isotretinoin, clomifene, etc.)
  • You will no longer need to underline high or unusual doses on a prescription
  • You will no longer need to report an explained loss of Schedule 8 or Schedule 4D medicines to Pharmaceutical Services. However, all losses of Schedule 8 medicines must be recorded in the drug register. Explained loss includes medicine lost in the dead space of a syringe, a witnessed spill, etc.

Schedule 4D medicine prescriptions will now be valid for 12 months

This is an increase from the previous period of 6 months. Schedule 4D medicines include those that are anabolic-androgenic steroidal medicines.

Changes to medicines requiring approval

The new Act and Regulation still require you to apply for an approval from the NSW Health to prescribe, issue a direction to supply or administer some medicines in certain situations.

Expanded exemptions from approval requirements

More exemptions now apply to the requirement for an approval. These have been broadened to recognise specialist expertise and the specific circumstances of certain patients, for example, when prescribing, supplying, or administering a medicine for palliative treatment. See full list of exemptions.

New approval requirements for morphine, oxycodone, fentanyl, and hydromorphone

The Act and Regulation strengthen controls to mitigate the increased risks associated with high-dose opioid prescribing and supply.

An approval is now required to prescribe, supply, or administer morphine, oxycodone, fentanyl, or hydromorphone, used individually or in combination, in a total daily dose exceeding 100mg oMEDD (oral Morphine Equivalent Daily Dose).

Some exemptions apply and include prescribing up to a 3-day supply for urgent pain relief. This applies in all settings and for all patients.

When prescribing Schedule 8 medicines, the key principles listed at Safe prescribing of high-risk medicines should be followed.

Other changes to approval requirements

  • Nominated Schedule 4 medicine (e.g., isotretinoin, clomifene, tretinoin, etc.):
    • More exemptions now apply
    • Prescriptions do not need to be endorsed with any statement to be valid for dispensing
  • Any Schedule 8 medicine for a person with substance-dependence:
  • Schedule 8 psychostimulant medicines (dexamfetamine, methylphenidate, lisdexamfetamine):
    • More exemptions now apply
    • Limits on doses that previously applied to psychiatrists, paediatricians, and neurologists have been removed.
  • The following medicines, when known to have been used continuously, individually or in combination for more than 3 months:
      • Schedule 8 medicines when in a formulation for injection or intranasal use
      • alprazolam
      • flunitrazepam
      • methadone (except when used under the NSW Opioid Treatment Program)
    • Approval is required when known to have been used continuously for more than 3 months* (previously 2 months). This applies to these medicines if used individually or in combination.
    • Some exemptions apply.
  • Pharmacy compounded Schedule 8 medicines:
    • No longer requires an approval unless it falls into the above approval requirements, such as use in a substance-dependent person, or is one of the specified medicines and circumstances above.
  • Schedule 8 psilocybine for treatment-resistant depression:
    • No change – approval is still required
    • Further restrictions apply - for more information refer to Psilocybine and MDMA.
  • Schedule 8 MDMA for the treatment of post-traumatic stress disorder:
    • No change – approval is still required
    • Further restrictions apply - for more information refer to Psilocybine and MDMA.

More information on approvals and how to apply can be found on the Medicine approvals webpage.

Opioid Treatment Program (OTP) requirements have changed

Registration and notification are now required to prescribe, supply, and administer medicines under the NSW OTP. To register and notify these activities, use SafeScript NSW.

OTP Standards now guide the activities under the OTP and compliance is mandatory.

Prescriptions for OTP medicines must not be given to the patients. They must be sent directly to the pharmacy for dispensing.

More information is available on NSW Opioid Treatment Program.

New mandatory standards are now in force

All health practitioners must comply with:

  • Opioid Treatment Program Standards - for the treatment of patients under the OTP
  • Medicines Storage Standards - for the safe and secure storage of Schedule 4D and Schedule 8 medicines
  • Electronic Drug Register Standards - for the requirements on the use of electronic drug registers to record transactions of S8 medicines
  • Vaccination Standards - for the safe and appropriate storage and administration of vaccines.

These standards will be published and circulated as soon as they become available.

More than one product may be included on an S8 prescription for the same medicine

For example, multiple strengths of morphine could be written on the same prescription. Each listed item must still comply with the prescription requirements in the Regulation.

Note, separate requirements may apply for medicines subsidised under the PBS.

Drug registers: stocktake now required every 3 months

You must now record the balance of Schedule 8 medicines in a drug register at least once every 3 months. Previously, this was only required in March and September.

For private and public hospitals, the stocktake requirement remains 6-monthly and may be conducted in any month (it is no longer limited to March and September).

In private practice, an authorised practitioner is responsible for keeping a compliant drug register on the practice premises where Schedule 8 medicines are kept. Please ensure you are aware of any obligations you may have.

Urgent use medicines from pharmacies are restricted to registered products only

Unregistered products are no longer permitted to be supplied as urgent use medicines.

  • You can only request to obtain registered Schedule 4 and 8 medicines for emergency or urgent use from a pharmacy. The registered medicine isn't restricted to those listed on the PBS Prescriber Bag orders.
  • Medical practitioners must provide a written and signed order for the pharmacist to supply the registered medicine. A record of the request for this supply must be kept for two years.

If you need medicines for non-urgent use, you can continue to obtain these from a wholesaler.

Self-prescribing of Schedule 8 and Schedule 4D medicines is no longer permitted

You can no longer self-prescribe Schedule 8 and Schedule 4D medicines or obtain them via wholesale for self-administration.

Information on self-prescribing and prescribing for family members is available in the Good medical practice: a code of conduct for doctors in Australia.

Other changes

Restrictions to medicine samples

Samples of Schedule 4D and Schedule 8 medicines are no longer permitted. You must issue a written order for samples for other scheduled medicines.

Compliance with policies and procedures is mandatory in some settings

If you work in a public health entity, you must continue to comply with NSW Ministry of Health Policy Directive on Medicines Handling.

If you work in a private health facility or private correctional centre, you must comply with the facility or centre's medicines policies and procedures.

Labelling requirements are listed in Appendix L of the Poisons Standard

The labelling of scheduled substances is no longer listed in the Regulation. Scheduled substances must be labelled as per the requirements of the Poisons Standard.

With the exception of OTP prescriptions, a pharmacist will no longer need to retain the repeat paper prescription for a Schedule 8 or Schedule 4D medicine on the pharmacy premises

Repeats can be given back to the patient to have dispensed at their pharmacy of choice.

Handwritten prescriptions must be legible.

Cosmetic use substances

Refer to Cosmetic use substances for information on the requirements for health practitioners and businesses that obtain, prescribe, supply or administer cosmetic use substances.

New restrictions on the supply of nitrous oxide

To reduce the harms associated with nitrous oxide misuse, while maintaining access for medical and industrial purposes and legitimate food preparation, new restrictions will apply to the supply of nitrous oxide. These include controls on:

  • retail sale
  • purchase limits
  • sales hours
  • online delivery
  • product storage
  • record-keeping requirements for certain businesses

Detailed information on these new restrictions is available on Nitrous oxide regulations.

New offences and increased penalties

The Act and Regulation set out penalties for offences associated with unauthorised activities.

Penalties are classified in 5 tiers and differ for individuals and corporations. They range from 20 to 400 penalty units for individuals and 100 to 2000 penalty units for corporations.

More information can be found in the offences and penalties section of the Act and the Regulation. Further information on compliance notices and penalties will also be available at a later date.

New terminology and definitions

  • Schedule 8 substance or medicine replaces Drug of addiction
  • Schedule 4 substance or medicine replaces Restricted substance
  • Schedule 4D substance or medicine replaces Prescribed restricted substance, Schedule 4 Appendix D
  • Nominated Schedule 4 substance or medicine replaces Certain restricted substance
  • Schedule 4D substance that is an anabolic-androgenic steroidal substance replaces Special restricted substance, Schedule 4 Appendix B

Further definitions and terminology can be found at ​Key definitions and terminology.


More information

Supporting information to help understand the requirements of the legislation is available on Medicines, Poisons and Therapeutic Goods legislation.

Disclaimer

This information is provided for general guidance only. While reasonable care has been taken to ensure the accuracy, reliability, and currency of the information, users should refer to the Medicines, Poisons and Therapeutic Goods Act 2022 and the Medicines, Poisons and Therapeutic Goods Regulation 2026 for full and current legal requirements.

Current as at: Monday 6 July 2026
Contact page owner: Pharmaceutical Services